AIM ImmunoTech (NYSE: AIM) widens Q2 2026 loss but lifts cash to $9.9M
Rhea-AI Filing Summary
AIM ImmunoTech Inc. reported second-quarter 2026 results and progress on its lead drug Ampligen in metastatic pancreatic cancer. The company completed patient enrollment and Ampligen dosing in the Phase 2 DURIPANC study combining Ampligen with Imfinzi and engaged Thermo Fisher Scientific’s PPD business to support planned Phase 3 trial design. AIM highlighted prior Dutch Named Patient Program data where Ampligen achieved a median Overall Survival of 34.8 months versus 12.5 months for historical controls in a selected biomarker subset, and anticipates DURIPANC clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027.
Cash and cash equivalents were $9.9 million as of June 30, 2026, compared with approximately $3.0 million as of December 31, 2025, following multiple financing transactions and regaining full NYSE American listing compliance. For Q2 2026, research and development expenses were approximately $589,000 versus $1.2 million a year earlier, while general and administrative expenses rose to about $2.9 million from $1.5 million. Net loss was approximately $(3.8 million), or $(0.43) per share, compared with $(2.8 million), or $(3.68) per share, for Q2 2025. The company is also planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease.
Positive
- Cash and cash equivalents increased to $9.9 million as of June 30, 2026 from approximately $3.0 million at December 31, 2025, providing more resources to support ongoing clinical development and upcoming milestones.
- Completed enrollment and Ampligen dosing in the metastatic pancreatic cancer Phase 2 DURIPANC trial and engaged a major clinical research organization to support planning of a pivotal Phase 3 trial.
- Previously reported Dutch Named Patient Program data showed Ampligen achieving a median Overall Survival of 34.8 months vs. 12.5 months for historical controls in a key biomarker subset, supporting the planned Phase 3 design.
Negative
- Quarterly net loss widened to approximately $(3.8 million) in Q2 2026 from $(2.8 million) in Q2 2025, reflecting higher operating costs.
- General and administrative expenses nearly doubled to approximately $2.9 million in Q2 2026 from $1.5 million a year earlier, increasing the company’s cost base.
Filing Explained
The reported
Sources and calculations
- AIM ImmunoTech Form 8-K and Exhibit 99.1 (2026-08-07)
- AIM ImmunoTech second-quarter 2026 fundamentals (2026Q2)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $9,900,000 / ($4,590,000 / 90) = [object Object]
8-K Event Classification
Key Figures
Key Terms
Ampligen medical
Phase 2 DURIPANC study medical
immune checkpoint inhibitor medical
Named Patient Program regulatory
Overall Survival medical
TLR3 agonist medical
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did AIM (AIM) report for its second quarter 2026 net loss?
How much cash does AIM (AIM) have as of June 30, 2026?
What clinical progress did AIM (AIM) make in pancreatic cancer during Q2 2026?
When does AIM (AIM) expect DURIPANC trial data readouts?
How did AIM’s (AIM) operating expenses change in Q2 2026?
What additional programs is AIM (AIM) pursuing beyond pancreatic cancer?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On August 10, 2026, AIM ImmunoTech Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and, other than the quotes by Thomas Equels, is incorporated herein by reference.
The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by AIM ImmunoTech Inc., whether made before or after the date hereof regardless of any general incorporation language in such filing.
| Item 9 .01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press Release, dated August 10, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 10, 2026 | AIM ImmunoTech Inc. |
| /s/ Thomas K. Equels | |
| Thomas K. Equels | |
| Chief Executive Officer |
Exhibit 99.1
CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
Completed Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027
Pancreatic
Cancer Remains Strategic Priority as AIM Advances Toward Planned Phase 3 Development While Seeking Select Government-Funded Infectious
Disease Initiatives in Ebola
OCALA, Fla., August 10, 2026 / AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the second quarter ended June 30, 2026, and provided a business update highlighting continued operational execution across its lead pancreatic cancer program.
“AIM continues to execute a clear and disciplined strategy centered on advancing Ampligen in pancreatic cancer,” said AIM Chief Executive Officer Thomas K. Equels. “Over the past year, we have strengthened our financial position while completing enrollment and Ampligen dosing in the metastatic pancreatic cancer Phase 2 clinical trial – critical steps as we move toward an anticipated Phase 3 study in metastatic pancreatic cancer. We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027. AIM expects that this data will amplify median Overall Survival findings from Ampligen’s Dutch-government approved Named Patient Program in late-stage pancreatic cancer, where Ampligen achieved a median Overall Survival of 34.8 months compared to 12.5 months for historical controls – with favorable safety profile and high quality of life – in a large, easily identifiable and key patient immune biomarker subset. This median improvement of 22.3 months will be a critical component of the foundation for our pivotal Phase 3 clinical trial design in metastatic pancreatic cancer.”
Second Quarter and Recent Operational Highlights
| ● | Completed patient enrollment and Ampligen dosing in the ongoing Phase 2 DURIPANC study evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in metastatic pancreatic cancer. | |
| ● | Engaged Thermo Fisher Scientific’s PPD clinical research business to support study design of a planned pivotal Phase 3 clinical trial in metastatic pancreatic cancer. | |
| ● | Maintained encouraging observations from Erasmus MC Cancer Institute, including favorable safety findings, progression-free and overall survival trends, and consistently reported high quality of life among treated patients. |
| 1 |
| ● | Strengthened the Company’s balance sheet through multiple financing transactions, providing additional resources to support continued clinical execution. | |
| ● | Successfully regained full compliance with NYSE American’s continued listing standards. | |
| ● | Planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease, consistent with the Company’s strategy of pursuing non-dilutive funding opportunities for select infectious disease programs while maintaining pancreatic cancer as its primary strategic focus. |
For more information, please visit the Company’s website at aimimmuno.com.
Summary of Financial Highlights for Second Quarter 2026
| ● | As of June 30, 2026, AIM reported $9.9 million in cash and cash equivalents, as compared to approximately $3.0 million as of December 31, 2025. | |
| ● | Research and development expenses for the three months ended June 30, 2026 were approximately $589,000, compared to $1.2 million during the same period in 2025. | |
| ● | General and administrative expenses were approximately $2.9 million for the second quarter of 2026, compared to $1.5 million during the same period in 2025. | |
| ● | Net loss for the three months ended June 30, 2026 was approximately $(3.8 million), or $(0.43) per share, compared to $(2.8 million), or $(3.68) per share, for the second quarter of 2025. |
The Company believes its strengthened financial position supports continued execution of its clinical development strategy and key upcoming milestones. Please refer to the Company’s Form 10-Q for the quarter ended June 30, 2026, for complete financial results and additional disclosures.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
| 2 |
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by those sections. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “believes,” “expects,” “intends,” “may,” “will,” “plans,” “potential,” “anticipates,” “projects,” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements set forth in this press release speak only as of the date hereof. These forward-looking statements are based upon the Company’s current expectations, estimates, assumptions, and beliefs concerning future events and conditions, which are subject to change. Such forward-looking statements may include statements relating to: the anticipated timing of DURIPANC study data, including clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027; anticipated survival outcomes, quality-of-life measures, and the safety profile of Ampligen; the Company’s financial position to support clinical development activities and key milestones; the pursuit of non-dilutive government funding opportunities for select infectious disease programs, including the evaluation of Ampligen’s antiviral potential against Ebola virus disease; the Company’s Phase 3 clinical trial planning efforts; the timing of commencement, enrollment, completion, and results of clinical trials; IP expansion and regulatory progress; and timing for receiving government approvals, if at all. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
For a detailed discussion of risk factors that could cause actual results to differ materially from those described in the forward-looking statements, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. The forward-looking statements in this press release should be read in conjunction with such filings. These filings are available at www.sec.gov and www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference into this press release and is included for reference purposes only.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
| 3 |